Robert B Jenkins

List of Publications by Year in Descending Order

166 papers	12,041 citations	53 h-index	108 g-index
172 ext. papers	14,153 ext. citations	6.9 avg, IF	5.56 L-index

#	Paper	IF	Citations
166	HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 883-886	5	0
165	SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA. *Frontiers in Genetics*, **2021**, 12, 739054	4.5	0
164	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. *Acta Neuropathologica*, **2021**, 141, 945-957	14.3	9
163	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. *Neuro-Oncology*, **2021**, 23, 1547-1559	1	7
162	RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch Repair. *Journal of Molecular Diagnostics*, **2021**, 23, 555-564	5.1	9
161	Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. *Radiology*, **2021**, 299, 313-323	20.5	10
160	Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results. *American Journal of Clinical Pathology*, **2021**, 156, 886-894	1.9	
159	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. *Human Pathology*, **2021**, 112, 20-34	3.7	2
158	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. *Lancet Oncology, The*, **2021**, 22, 813-823	21.7	24
157	Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?. *Brain Pathology*, **2021**, 31, 20-32	6	8
156	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. *Neuro-Oncology*, **2021**, 23, 457-467	1	18
155	Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors. *Neuro-Oncology*, **2021**, 23, 638-649	1	4
154	Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 804-806	3.1	
153	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. *Blood Cancer Journal*, **2021**, 11, 18	7	3
152	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 821-829	3.1	1
151	Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis. *Neuro-Oncology*, **2020**, 22, 207-215	1	12
150	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. *BMC Urology*, **2020**, 20, 173	2.2	1

149	Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C. *Neuro-Oncology*, **2020**, 22, 1602-1613	1	5
148	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 182, 613-622	4.4	
147	Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas. *Acta Neuropathologica*, **2020**, 139, 1105-1107	14.3	3
146	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathologica*, **2020**, 139, 603-608	14.3	170
145	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 21-22	2.2	
144	Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. *Neuro-Oncology Advances*, **2020**, 2, vdaa109	0.9	6
143	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. *Neuro-Oncology*, **2020**, 22, 1742-1756	1	7
142	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. *International Journal of Cancer*, **2020**, 146, 739-748	7.5	14
141	Desmoplastic Infantile Ganglioglioma: A MAPK Pathway-Driven and Microglia/Macrophage-Rich Neuroepithelial Tumor. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 1011-1021	3.1	11
140	Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood-Brain Barrier. *Molecular Cancer Therapeutics*, **2019**, 18, 2171-2181	6.1	6
139	Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. *Cancer Research*, **2019**, 79, 905-917	10.1	17
138	The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. *BMC Cancer*, **2019**, 19, 190	4.8	2
137	Using germline variants to estimate glioma and subtype risks. *Neuro-Oncology*, **2019**, 21, 451-461	1	8
136	RNA sequencing identifies a novel USP9X-USP6 promoter swap gene fusion in a primary aneurysmal bone cyst. *Genes Chromosomes and Cancer*, **2019**, 58, 589-594	5	16
135	Sex-specific gene and pathway modeling of inherited glioma risk. *Neuro-Oncology*, **2019**, 21, 71-82	1	19
134	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 791-797	3.1	25
133	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. *Neuroradiology*, **2019**, 61, 1327-1332	3.2	18
132	A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. *Prostate*, **2019**, 79, 1589-1596	4.2	6

131	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. *Neuro-Oncology*, **2019**, 21, 1458-1469		27
130	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. *Neuro-Oncology*, **2019**, 21, 1498-1508	1	25
129	Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma. *Cancer Research*, **2019**, 79, 2065-2071	10.1	16
128	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. *Cancer Cell*, **2019**, 35, 401-413.e6	24.3	74
127	Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 16, 258-266	6	27
126	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 87-96	3.8	23
125	Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 555-562	4	11
124	Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. *Journal of Neurology*, **2018**, 265, 1432-1442	5.5	19
123	Mendelian randomisation study of the relationship between vitamin D and risk of glioma. *Scientific Reports*, **2018**, 8, 2339	4.9	12
122	SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). *Cancer Genetics*, **2018**, 221, 1-18	2.3	57
121	Impact of atopy on risk of glioma: a Mendelian randomisation study. *BMC Medicine*, **2018**, 16, 42	11.4	27
120	Influence of obesity-related risk factors in the aetiology of glioma. *British Journal of Cancer*, **2018**, 118, 1020-1027	8.7	22
119	Molecular subtyping of tumors from patients with familial glioma. *Neuro-Oncology*, **2018**, 20, 810-817	1	6
118	Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series. *Urology*, **2018**, 112, 29-32	1.6	1
117	Copy number variant analysis using genome-wide mate-pair sequencing. *Genes Chromosomes and Cancer*, **2018**, 57, 459-470	5	38
116	Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. *Scientific Reports*, **2018**, 8, 7352	4.9	30
115	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1376-1383	4	5
114	Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. *Journal of Molecular Diagnostics*, **2018**, 20, 495-511	5.1	28

113	Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy. *Acta Neuropathologica Communications*, **2018**, 6, 118	7.3	7
112	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathologica*, **2018**, 136, 805-810	14.3	367
111	Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. *International Journal of Cancer*, **2018**, 143, 2359-2366	7.5	13
110	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. *Clinical Cancer Research*, **2018**, 24, 3908-3916	12.9	10
109	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. *American Journal of Neuroradiology*, **2017**, 38, 678-684	4.4	45
108	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. *Clinical Genitourinary Cancer*, **2017**, 15, e299-e309	3.3	20
107	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. *Oncogene*, **2017**, 36, 3417-3427	9.2	47
106	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. *BJU International*, **2017**, 119, 961-967	5.6	5
105	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. *Acta Neuropathologica*, **2017**, 133, 1001-1016	14.3	185
104	Management of diffuse low-grade gliomas in adults - use of molecular diagnostics. *Nature Reviews Neurology*, **2017**, 13, 340-351	15	72
103	IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2 Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. *Clinical Cancer Research*, **2017**, 23, 4203-4211	12.9	4
102	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. *Nature Genetics*, **2017**, 49, 789-794	36.3	163
101	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. *Cancer Research*, **2017**, 77, 1021-1034	10.1	74
100	Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. *World Neurosurgery*, **2017**, 108, 997.e9-997.e14	2.1	3
99	OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma. *Neuro-Oncology*, **2017**, 19, iii10-iii11	1	1
98	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. *Clinical Cancer Research*, **2017**, 23, 7072-7083	12.9	61
97	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. *Lancet, The*, **2017**, 390, 1645-1653	40	225
96	Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. *Neuro-Oncology*, **2017**, 19, 128-137	1	121

95	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. *Journal of Urology*, **2017**, 197, 122-128	2.5	29
94	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. *Oncotarget*, **2017**, 8, 27145-27154	3.3	40
93	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. *Oncotarget*, **2017**, 8, 18949-18967	3.3	38
92	Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. *Acta Neuropathologica*, **2017**, 134, 317-319	14.3	3
91	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	66
90	History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC). *Cancer Medicine*, **2016**, 5, 1352-8	4.8	23
89	Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 282-90	4	66
88	Statistical considerations on prognostic models for glioma. *Neuro-Oncology*, **2016**, 18, 609-23	1	10
87	Understanding inherited genetic risk of adult glioma - a review. *Neuro-Oncology Practice*, **2016**, 3, 10-16	2.2	42
86	Impact of RNA degradation on fusion detection by RNA-seq. *BMC Genomics*, **2016**, 17, 814	4.5	24
85	PPP6R3-USP6 amplification: Novel oncogenic mechanism in malignant nodular fasciitis. *Genes Chromosomes and Cancer*, **2016**, 55, 640-9	5	33
84	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. *Prostate*, **2016**, 76, 597-608	4.2	13
83	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. *Modern Pathology*, **2016**, 29, 764-71	9.8	47
82	Telomere maintenance and the etiology of adult glioma. *Neuro-Oncology*, **2015**, 17, 1445-52	1	53
81	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. *European Urology*, **2015**, 68, 555-67	10.2	100
80	A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. *Cancer Research*, **2015**, 75, 4884-94	10.1	30
79	High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2015**, 18, 229-36	6.2	7
78	Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. *European Urology*, **2015**, 67, 326-33	10.2	135

77	Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. *PLoS ONE*, **2015**, 10, e0116866	3.7	9
76	Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *New England Journal of Medicine*, **2015**, 372, 2499-508	59.2	1181
75	Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis. *Medical Epigenetics*, **2015**, 3, 1-18		7
74	Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. *BJU International*, **2015**, 116, 556-67	5.6	14
73	Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. *Journal of Clinical Oncology*, **2015**, 33, 701-8	2.2	142
72	Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. *PLoS ONE*, **2015**, 10, e0141506	3.7	73
71	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. *Oncotarget*, **2015**, 6, 30295-305	3.3	86
70	Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. *Oncotarget*, **2015**, 6, 42468-77	3.3	66
69	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. *Journal of Clinical Oncology*, **2014**, 32, 783-90	2.2	280
68	Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. *Nature Genetics*, **2014**, 46, 731-5	36.3	141
67	Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. *PLoS ONE*, **2014**, 9, e97655	3.7	21
66	A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. *Prostate Cancer and Prostatic Diseases*, **2014**, 17, 64-9	6.2	102
65	Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. *Molecular Therapy*, **2014**, 22, 547-553	11.7	39
64	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. *Lancet Oncology, The*, **2014**, 15, 1469-1480	21.7	192
63	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. *Nature Communications*, **2014**, 5, 5383	17.4	432
62	Missense SNP rs3731249 Explains the CDKN2A Association with Childhood ALL and Shows Risk Allele Selection in Tumors with Somatic CDKN2A Alterations. *Blood*, **2014**, 124, 129-129	2.2	1
61	Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.. *Journal of Clinical Oncology*, **2014**, 32, 93-93	2.2	
60	Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *Journal of Clinical Oncology*, **2013**, 31, 337-43	2.2	767

59	Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. *Neuro-Oncology*, **2013**, 15, 1041-7	1	36
58	Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.. *Journal of Clinical Oncology*, **2013**, 31, 36-36	2.2	
57	A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. *Nature Genetics*, **2012**, 44, 1122-5	36.3	108
56	Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.. *Journal of Clinical Oncology*, **2012**, 30, 90-90	2.2	1
55	Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 4565-4565	2.2	
54	Development and validation of a digital Gleason score biomarker signature for risk stratification of patients with prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 40-40	2.2	
53	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nature Genetics*, **2011**, 43, 1098-103	36.3	203
52	Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. *Cancer Genetics*, **2011**, 204, 13-8	2.3	62
51	Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. *Nature Genetics*, **2009**, 41, 905-8	36.3	396
50	Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. *Brain Pathology*, **2008**, 18, 360-9	6	107
49	A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer Research*, **2006**, 66, 9852-61	10.1	563
48	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. *Genes Chromosomes and Cancer*, **2005**, 42, 68-77	5	80
47	Reply to Palacios et al., ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers *Genes Chromosomes and Cancer*, **2005**, 42, 206-206	5	
46	Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.. *Blood*, **2005**, 106, 2098-2098	2.2	3
45	N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis. *Journal of Clinical Oncology*, **2005**, 23, 1505-1505	2.2	4
44	NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). *Journal of Clinical Oncology*, **2004**, 22, 1503-1503	2.2	5
43	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. *Journal of Clinical Oncology*, **2004**, 22, 1508-1508	2.2	2
42	HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. *Journal of Clinical Oncology*, **2004**, 22, 567-567	2.2	7

41	Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. *Journal of Clinical Oncology*, **2004**, 22, 568-568	2.2	6
40	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. *Journal of Clinical Oncology*, **2004**, 22, 1508-1508	2.2	2
39	Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 1099-104	3.1	87
38	Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. *Acta Neuropathologica*, **2001**, 101, 605-15	14.3	24
37	Genetic alterations and chemotherapeutic response in human diffuse gliomas. *Expert Review of Anticancer Therapy*, **2001**, 1, 595-605	3.5	21
36	Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. *Genetic Testing and Molecular Biomarkers*, **2001**, 5, 101-6		28
35	Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. *Modern Pathology*, **2001**, 14, 842-53	9.8	97
34	Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. *Journal of Clinical Oncology*, **2000**, 18, 636-45	2.2	899
33	Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. *American Journal of Medical Genetics Part A*, **2000**, 92, 136-41		46
32	Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. *Genes Chromosomes and Cancer*, **2000**, 27, 1-10	5	48
31	Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. *Genes Chromosomes and Cancer*, **2000**, 27, 95-103	5	87
30	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chromosomes and Cancer*, **2000**, 29, 16-25	5	11
29	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chromosomes and Cancer*, **2000**, 29, 16-25	5	70
28	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. *Oncogene*, **1999**, 18, 2343-50	9.2	438
27	A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. *Oncogene*, **1999**, 18, 3913-8	9.2	31
26	Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. *Oncogene*, **1999**, 18, 4144-52	9.2	311
25	Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer **1999**, 24, 48-55		28
24	Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. *Genes Chromosomes and Cancer*, **1999**, 25, 65-9	5	5

23	Mutation and expression analysis of the p73 gene in prostate cancer. *Prostate*, **1999**, 39, 94-100	4.2	26
22	FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. *Oncogene*, **1998**, 16, 2311-9	9.2	66
21	Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. *Oncogene*, **1998**, 16, 635-42	9.2	28
20	Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. *Cancer*, **1998**, 83, 1995-2002	6.4	156
19	Familial chordoma with probable autosomal dominant inheritance. *American Journal of Medical Genetics Part A*, **1998**, 75, 335-6		36
18	Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. *Genes Chromosomes and Cancer*, **1998**, 21, 131-143	5	74
17	Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. *Genes Chromosomes and Cancer*, **1998**, 21, 152-9	5	60
16	Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer **1998**, 21, 131		3
15	A molecular cytogenetic analysis of 7q31 in prostate cancer. *Cancer Research*, **1998**, 58, 759-66	10.1	59
14	Chromosomal Anomalies in Stage D1 Prostate Adenocarcinoma Primary Tumors and Lymph Node Metastases Detected by Fluorescence in Situ Hybridization. *Journal of Urology*, **1997**, 157, 223-227	2.5	46
13	Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. *Cancer Research*, **1997**, 57, 524-31	10.1	313
12	Application of fluorescent in situ hybridization with X and Y chromosome specific probes to buccal smear analysis. *American Journal of Medical Genetics Part A*, **1996**, 66, 187-92		17
11	Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. *Cancer*, **1996**, 77, 2567-73	6.4	54
10	Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. *International Journal of Urology*, **1995**, 2, 215-23	2.3	2
9	Uniparental disomy in congenital disorders: a prospective study. *American Journal of Medical Genetics Part A*, **1995**, 58, 143-6		12
8	Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: correlation with stage and CD20 antigen expression intensity. *Leukemia and Lymphoma*, **1994**, 14, 447-51	1.9	19
7	Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. *Cancer*, **1994**, 74, 920-7	6.4	74
6	Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. *American Journal of Clinical Pathology*, **1992**, 98, 502-10	1.9	43

5	Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. *Genes Chromosomes and Cancer*, **1992**, 5, 348-56	5	156
4	Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. *Genes Chromosomes and Cancer*, **1992**, 5, 357-74	5	102
3	Prognostic value of cytogenetic analysis in human cerebral astrocytomas. *Annals of Neurology*, **1992** , 31, 534-42	9.4	45
2	Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. *Blood*, **1992**, 79, 3307-15	2.2	91
1	TP53 gene mutations and 17p deletions in human astrocytomas. *Genes Chromosomes and Cancer*, **1991**, 3, 323-31	5	117